Search results
Results From The WOW.Com Content Network
Ranbaxy's Malvinder Singh remained as CEO after the transaction. [11] The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations, with the combined company worth about US$30 billion. [12] In 2009, it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the Indian operations of Ranbaxy Laboratories. [13] [14]
In 2006, Advent had sold 96.7% of the company to Ranbaxy. Terapia S.A. therefore went through a brand name change, and so it became Terapia Ranbaxy. Two years later, the Japanese pharmaceutical giant Daiichi Sankyo had purchased 1/5 of the company, and so Terapia Ranbaxy became part of the giant.
Ranbaxy was way more than simply "laden with controversy" as currently stated in the introduction, and the Controversies section currently does not make it clear that the company's "whose business model was completely dependent on falsifying data in their drug applications to the FDA" (in the words of Katherine Eban's interviewer).
For premium support please call: 800-290-4726 more ways to reach us
From January 2008 to April 2011, if you bought shares in companies when Gail D. Fosler joined the board, and sold them when she left, you would have a 59.1 percent return on your investment, compared to a -7.1 percent return from the S&P 500.
From January 2008 to December 2012, if you bought shares in companies when John S. Chen joined the board, and sold them when he left, you would have a 42.4 percent return on your investment, compared to a -2.8 percent return from the S&P 500.
The following other wikis use this file: Usage on ar.wikipedia.org رانباكسي; Usage on azb.wikipedia.org رانباکسی لابراتورو
(The Center Square) — New York will usher in a host of new laws in 2025 that will expand paid leave and worker's compensation benefits, reduce the cost of insulin for diabetes patients and make ...